Omnicell increases revolving commitment to $315 million

By Wendy Van Sickle

Columbus, Ohio, Dec. 27 – Omnicell, Inc. amended its credit facility dated Jan. 5, 2016 on Tuesday to increase the revolving credit facility to $315 million from $200 million, according to an 8-K filing with the Securities and Exchange Commission.

The credit agreement also provides for a $200 million term loan. Each credit facility is due Jan. 5, 2021.

Wells Fargo Securities, LLC is the lead arranger, and Wells Fargo Bank, NA is the administrative agent.

Borrowings bear interest at Libor plus a margin ranging from 150 basis points to 225 bps, depending on the company’s consolidated total net leverage ratio. The revolving commitment fee ranges from 20 bps to 35 bps.

Omnicell is a Mountain View, Calif.-based company that provides automated services for medication and supply management in health care in the United States and internationally.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.